scholarly journals Diagnosis and treatment of advanced breast cancer: summary of NICE guidance

BMJ ◽  
2009 ◽  
Vol 338 (feb25 1) ◽  
pp. b509-b509 ◽  
Author(s):  
N Murray ◽  
J Winstanley ◽  
A Bennett ◽  
K Francis ◽  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Diagnosis And Treatment ◽  
Nice Guidance

scholarly journals 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017

2018 ◽  
Vol 78 (05) ◽  
pp. 469-480
Author(s):  
Michael Untch ◽  
Rachel Würstlein ◽  
Norbert Marschner ◽  
Diana Lüftner ◽  
Doris Augustin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Advanced Breast Cancer ◽  
Metastatic Breast ◽  
Consensus Conference ◽  
Advanced Breast ◽  
Diagnosis And Treatment ◽  
Parp Inhibition ◽  
Molecular Testing ◽  
The World

AbstractThe fourth international advanced breast cancer consensus conference (ABC4) on the diagnosis and treatment of advanced breast cancer (ABC) headed by Professor Fatima Cardoso was once again held in Lisbon on November 2 – 4, 2017. To simplify matters, the abbreviation ABC will be used hereinafter in the text. In clinical practice, the abbreviation corresponds to metastatic breast cancer or locally far-advanced disease. This year the focus was on new developments in the treatment of ABC. Topics discussed included the importance of CDK4/6 inhibition in hormone receptor (HR)-positive ABC, the use of dual antibody blockade to treat HER2-positive ABC, PARP inhibition in triple-negative ABC and the potential therapeutic outcomes. Another major area discussed at the conference was BRCA-associated breast cancer, the treatment of cerebral metastasis, and individualized treatment decisions based on molecular testing (so-called precision medicine). As in previous years, close cooperation with representatives from patient organizations from around the world is an important aspect of the ABC conference. This cooperation was reinforced and expanded at the ABC4 conference. A global alliance was founded at the conclusion of the consensus conference, which aims to promote and coordinate the measures considered necessary by patient advocates worldwide. Because the panel of experts was composed of specialists from all over the world, it was inevitable that the ABC consensus also reflected country-specific features. As in previous years, a team of German breast cancer specialists who closely followed the consensus voting of the ABC panelists in Lisbon and intensively discussed the votes has therefore commented on the consensus in the context of the current German guidelines on the diagnosis and treatment of breast cancer 1, 2 used in clinical practice in Germany. The ABC consensus is based on the votes of the ABC panelists in Lisbon.

scholarly journals ABC4 Consensus: Assessment by a German Group of Experts

Breast Care ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. 48-58 ◽  
Author(s):  
Nadia Harbeck ◽  
Diana Lüftner ◽  
Norbert Marschner ◽  
Michael Untch ◽  
Doris Augustin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Growth Factor Receptor ◽  
Advanced Breast ◽  
Diagnosis And Treatment ◽  
Parp Inhibition ◽  
Molecular Testing ◽  
Her2 Positive ◽  
Global Alliance ◽  
Therapy Decision

The Advanced Breast Cancer Fourth Consensus (ABC4) on diagnosis and treatment of advanced breast cancer (ABC) again took place in Lisbon, on November 2-4, 2017, and was chaired by Fatima Cardoso, MD, PhD. This year's contents focused very much on new developments in the treatment of ABC. For example, the significance of inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) in hormone receptor (HR)-positive ABC, of dual antibody blockade in human epidermal growth factor receptor 2 (HER2)-positive ABC, and of poly(ADP-ribose) polymerase (PARP) inhibition in triple-negative ABC, as well as the potential therapeutic consequences, were discussed. Other key issues were BRCA-associated breast cancer, treatment of brain metastases, and personalized therapy decision-making using molecular testing (so-called ‘precision medicine'). As in past years, an important objective of the ABC conference was cooperation with representatives of patient organizations from around the world. This cooperation was further intensified during the ABC4. Following the main conference, the ‘Global Alliance' was founded, with the goal of publicizing and coordinating measures necessary worldwide from the patient advocates' standpoint. - The ABC consensus inevitably cannot accommodate country-specific needs, due to the truly global expert panel. Therefore, a working group of German breast cancer experts commented - as in the past years - on the on-site voting results by the ABC panelists upon which the final ABC4 consensus will be based, with particular consideration of the German guidelines on diagnosis and treatment of breast cancer for everyday treatment in Germany.

scholarly journals ABC3 Consensus: Assessment by a German Group of Experts

Breast Care ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. 61-70 ◽  
Author(s):  
Christoph Thomssen ◽  
Doris Augustin ◽  
Johannes Ettl ◽  
Renate Haidinger ◽  
Hans-Joachim Lück ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Working Group ◽  
Medical Oncology ◽  
Treatment Success ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Diagnosis And Treatment ◽  
Individual Treatment ◽  
Patient Reported

The Advanced Breast Cancer Third International Consensus Conference on the diagnosis and treatment of advanced breast cancer took place in Lisbon, Portugal, on November 5-7, 2015. This year's conference (ABC3) was focused on the treatment of metastatic breast cancer (stage IV), as it was 4 years ago at the first consensus meeting (ABC1). A matter of particular interest was the patients' perspective. Thus, patient-relevant issues were addressed by the consensus discussions, such as those on treatment goals, quality of life, care of long-term survivors (‘survivorship issues'), and coping with disease-related symptoms and the side effects of treatment. Further important issues on the agenda were the use of standardized instruments for the assessment of individual treatment success (‘patient-reported outcome measures') and the evaluation of the benefit of novel drugs (e.g. the European Society for Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale). Diagnosis and treatment of inoperable locally advanced breast cancer had already been discussed 2 years earlier at the ABC2 Consensus and were not dealt with in the framework of this year's ABC3 Consensus. With regard to country-specific peculiarities, which unavoidably found their way into the ABC Consensus, a working group of German breast cancer experts commented on the voting results of the ABC panelists. As for the past consensus, the group specially considered the German guidelines for the diagnosis and treatment of breast cancer (AGO (Gyneco-Oncology Working Group), S3, DGHO (German Society of Hematology and Medical Oncology)) in order to adapt the ABC3 consensus for everyday therapy in Germany.

NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer

2016 ◽  
Vol 17 (2) ◽  
pp. 143-144 ◽  
Author(s):  
Ahmed Elsada ◽  
Sally Doss ◽  
Janet Robertson ◽  
E Jane Adam
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Nice Guidance

scholarly journals Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)

Cancer ◽  
2020 ◽  
Vol 126 (S16) ◽  
pp. 3867-3882 ◽  
Author(s):  
Binghe Xu ◽  
Xichun Hu ◽  
Jifeng Feng ◽  
Cuizhi Geng ◽  
Feng Jin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Clinical Diagnosis ◽  
Advanced Breast ◽  
Expert Consensus ◽  
Diagnosis And Treatment

scholarly journals PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021

2021 ◽  
Vol 23 (2) ◽  
pp. 269-274
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Clinical Case ◽  
Pik3ca Mutation ◽  
Metastatic Breast ◽  
Advanced Breast ◽  
Diagnosis And Treatment ◽  
Breast Cancer Therapy ◽  
Target Drug ◽  
Shared Information

А virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with the PIK3CA mutation using target drug alpelisib was held on April 23, 2021. Oncologists from France and Russia discussed the significance of the PIK3CA mutation, the necessity and methods of its identification. They also shared information and exchanged experience of using alpelisib to treat patients who had previously received a CDK4/6 inhibitor and were resistant to endocrine therapy. Using the example of a clinical case, the experts also discussed the issues of prevention and correction of adverse events.

Sign in / Sign up

Export Citation Format

Share Document